Roche's MabThera receives EU approval for the most common type of leukaemia
This article was originally published in Scrip
Executive Summary
Roche's monoclonal antibody drug MabThera (rituximab) has received an EU marketing approval as a first line treatment for chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults.